Allelix Biopharmaceuticals Inc.

1149336 Ontario, Inc.

Open Text S.a.

Nps Pharmaceuticals, Inc.

Nps Allelix Corporation

Martin Sumner-Smith

Daniel J Drucker

Anna E Crivici

Lorne S Reid

Richard W Barnett

Matthew David George Timmermans

Paul Thomas Jenkins

Willard Carter Morton, Jr

Cheryl Lynne McKinnon

Florian Müller

Daniel Wray Barkley

Michael Twist

Robert W Boender

Nahum Sonenberg

Adam Murray Howatson

Michael Twist, Deceased

Analogs of glucagon-like peptide 2, a product of glucagon gene expression, have been identified as intestinal tissue growth factors. Their formulation as pharmaceutical, and therapeutic use in treating disorders of the small bowel, are described.

Glucagon-like peptide-2 analogs

A method and system for providing a consistent flow documents and data content across different organizational units of a company or agency where the documents and data come from different enterprise systems and data stores but are related to linked processes that share models for organizing the content in the business context and in a format that enables a user to relate the content to the process step or steps they are performing. The system includes a network service that enables a configuration utility to automatically discover the objects and metadata and provides for a mapping of selected fields of the metadata to regions displayed in the user interface view with provision for filtering the data by mapping selected fields to a user input form. Thereby, a business analyst can create solutions without writing and maintaining complex program logic for each combination of presentation environment, enterprise system and data store.

Method and system for managing enterprise content

Antagonists of glucagon-like peptide 2, have been identified. Their effects on the growth of gastrointestinal tissue are described. Its formulation as a pharmaceutical, and its therapeutic and related uses in treating bowel tissue, are described. Also described are methods of identifying antagonists of glucagon-like peptide 2.

Antagonists of intestinotrophic GLP-2 peptides

Intestinotrophic glucagon-like peptide-2 analogs

Described herein are oligopeptides useful to inhibit replication of herpesviruses, especially herpes simplex viruses. In a preferred embodiment of the invention, the oligopeptide is a D-arginine nonamer having N- and C-terminal protecting groups, which, at a 5 uM concentration, exhibits greater than 95% inhibition of HSV-1 replication, in a standard assay.

Treatment of herpesvirus infection

Described herein are oligopeptides useful to inhibit replication in virally infected individuals. In a preferred embodiment of the invention, the oligopeptide is a D-arginine nonamer having N- and C-terminal protecting groups, which, at a 3 uM concentration, exhibits greater than 95% inhibition of HIV replication, in a standard assay.

Peptide-based inhibitors of HIV replication

An anti-viral composition includes a synergistic combination of an anti-viral nucleoside analogue, which may inhibit a virus-specific enzyme, such as viral thymidine kinase and reverse transcriptase, an anti-viral oligonucleotide compound having from 6 to 12 amino acid residues substantially all of which are D-arginine residues, and a pharmaceutically acceptable carrier. A method for treating a viral infection is also described.

Anti-viral compositions

Described herein are oligopeptides useful to inhibit replication in virally infected individuals. In a preferred embodiment of the invention, the oligopeptide is a D-arginine nonamer having N- and C-terminal protecting groups, which, at a 5 uM concentration, exhibits greater than 95% inhibition of HIV replication, in a standard assay.

Described herein are anti-cytomegalovirus peptides. In a preferred embodiment, the peptide is acetyl-[D-Arg].sub.9 -NH.sub.2. The use of these peptides, either per se or in combination with other anti-CMV compounds, is disclosed as an effective method for controlling CMV infection.

Growing community of inventors

Palgrave, Canada

Martin Sumner-Smith